| Nu Pharmas, Inc. Acquires Renaissance Nutraceuticals and Appoints ...
SARASOTA, FL and WILSONVILLE, OR -- (MARKET WIRE) -- February 01, 2007 -- Nu Pharmas, Inc. (NPI), a contract manufacturer of oligonucleotide products as well as a development company of OTC homeopathic products and pharmaceuticals, announced today that it has acquired the assets of Renaissance Nutraceuticals, Inc. (RNI). Terms of the acquisition were not disclosed. Effective immediately, Steve Parkinson, RNI's Chairman and Chief Executive Officer, has been named President and Chief Executive Officer of the newly merged company. NPI Founding Scientist, Roderic M. K. Dale, Ph.D. remains with the company as Chairman of the Board and Chief Scientific Officer. Mr. Parkinson has successfully managed several early-stage biotechnology companies from conception to commercial operation.
A Sinner's Guide to Offshoring
Organizations that outsource operations to offshore environments consistently save money by taking advantage of lower labor costs. While that's not surprising, evidence increasingly suggests that most offshore initiatives could do much better at improving cost efficiency. Compass analyses indicate that both captive and outsourced offshore projects are often poorly planned, shoddily implemented and ineffectively managed. As a result, cost savings from these initiatives fall far short of their potential. In many cases, the failures result not from a lack of capabilities, experience or resources, but from human foibles such as arrogance, laziness or greed. In other words, good old-fashioned sin is to blame. Consider these scenarios: Hubris Research shows that rushing through an offshoring project is counterproductive, yet surprisingly many executives seem to believe they're smarter than others and can therefore cut corners and abdicate the responsibilities associated with the implementation and ongoing management of an offshore operation.
Doctor seeks patients' helpin keeping drug costs down
Q. As a physician, I want to offer my perspective on the "sticker shock" problem in the pharmacy. I am very conscious of the fact that my patients may not be able to afford medications I prescribe.
Almost all medications have alternatives, and I wish I knew which would be cheapest when I am writing the prescription. Patients with drug coverage could save a lot of time and money if they brought the list of drugs covered by their insurance to every doctor visit.
I also want to know how much patients pay for drugs. I wish they would call the office if the prescription is too expensive! Most of the time, I'd be able to identify a cheaper alternative to prescribe.
A. We appreciate your thoughtful approach. A recent study showed that many doctors don't discuss the cost of prescriptions with their patients (American Journal of Managed Care, November 2006).
|
